Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACACIA RESEARCH CORPACTG · Entity 5559 | Director | September 15, 2026 | September 16, 2026 |
| Chemomab Therapeutics Ltd.ANCN · Entity 7653 | Director | January 01, 2020 | January 02, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACACIA RESEARCH CORP
Report date September 15, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ACTG Common StockSEC Table I · non-derivative | Direct | 54,310 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Sale · Disposed 24,000 · Balance 54,310 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.55 to $4.56, inclusive. The Reporting Person undertakes to provide to Acacia Research Corporation ("Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.55 to $4.56, inclusive. The Reporting Person undertakes to provide to Acacia Research Corporation ("Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form.
Chemomab Therapeutics Ltd.
Report date January 01, 2020 · Filed January 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock optionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2029-07-02 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-01-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: 1/3 of the options vest one year following the vesting commencement date of July 3, 2019, and 1/12 at the end of each calendar quarter thereafter, until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/3 of the options vest one year following the vesting commencement date of July 3, 2019, and 1/12 at the end of each calendar quarter thereafter, until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 16, 2026 21:18 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | SaleACTG Common Stock | 24,000 | $4.55 | $109,200.00 |
DisclosureSEC source: 0001776505-26-000015 · wk-form4_1789593490.xml · nonDerivative · entry 1 Kohlberg Isaac T. · CIK 0001776505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,310 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.55 to $4.56, inclusive. The Reporting Person undertakes to provide to Acacia Research Corporation ("Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:00 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | SaleACTG Common Stock | 32,188 | $4.67 | $150,317.96 |
DisclosureSEC source: 0001776505-26-000010 · wk-form4_1786737630.xml · nonDerivative · entry 1 Kohlberg Isaac T. · CIK 0001776505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,310 F1 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.66 to $4.69, inclusive. Mr. Kohlberg undertakes to provide to Acacia Research Corporation ("Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 20:12 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | GrantACTG Common Stock | 25,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001776505-26-000003 · wk-form4_1782418365.xml · nonDerivative · entry 1 Kohlberg Isaac T. · CIK 0001776505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,498 F1 · shares: Grant of restricted stock awarded on June 23, 2026, as part of the Company's annual grant of equity awards to non-employee directors, pursuant to the 2024 Acacia Research Corporation Stock Incentive Plan. 100% of the restricted stock will vest on the first anniversary of the grant date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 22:10 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | SaleACTG Common Stock | 16,000 | $3.84 | $61,440.00 |
DisclosureSEC source: 0001776505-25-000010 · wk-form4_1749852622.xml · nonDerivative · entry 1 Kohlberg Isaac T. · CIK 0001776505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,446 Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:20 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | GrantACTG Common Stock | 32,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001776505-25-000006 · wk-form4_1748982015.xml · nonDerivative · entry 1 Kohlberg Isaac T. · CIK 0001776505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,446 F1 · shares: Grant of restricted stock awarded on May 30, 2025, as part of the Company's annual grant of equity awards to non-employee directors, pursuant to the 2024 Acacia Research Corporation Stock Incentive Plan. 100% of the restricted stock will vest on the first anniversary of the grant date. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 21:01 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | SaleACTG Common Stock | 15,000 | $4.57 | $68,572.50 |
DisclosureSEC source: 0001776505-24-000009 · wk-form4_1732654891.xml · nonDerivative · entry 1 Kohlberg Isaac T. · CIK 0001776505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,274 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.5600 to $4.5850, inclusive. The Reporting Person undertakes to provide to Acacia Research Corporation ("Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:03 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | GrantACTG Common Stock | 23,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001776505-24-000003 · wk-form4_1718136211.xml · nonDerivative · entry 1 Kohlberg Isaac T. · CIK 0001776505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,274 F1 · shares: Grant of restricted stock awarded on June 7, 2024, as part of the Company's annual grant of equity awards to non-employee directors, pursuant to the 2024 Acacia Research Corporation Stock Incentive Plan. 100% of the restricted stock will vest on the first anniversary of the grant date. Read SEC document |
| May 26, 2023 Filed May 31, 2023 21:16 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | GrantACTG Common Stock | 30,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001776505-23-000002 · wk-form4_1685567780.xml · nonDerivative · entry 1 Kohlberg Isaac T. · CIK 0001776505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,153 F1 · shares: Grant of restricted stock awarded on May 26, 2023, as part of the Company's annual grant of equity awards to non-employee directors, pursuant to the 2016 Acacia Research Corporation Stock Incentive Plan. 100% of the restricted stock will vest on the first anniversary of the grant date. Read SEC document |
| May 09, 2022 Filed May 11, 2022 18:10 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | GrantACTG Common Stock | 26,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001776505-22-000006 · wf-form4_165229264059615.xml · nonDerivative · entry 1 Kohlberg Isaac T. · CIK 0001776505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,619 F1 · shares: Grant of restricted stock awarded on May 9, 2022, as part of the Company's annual grant of equity awards to non-employee directors, pursuant to the 2016 Acacia Research Corporation Stock Incentive Plan. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 17:09 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | GrantACTG Common Stock | 4,418 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-21-004627 · ownership.xml · nonDerivative · entry 1 Kohlberg Isaac T. · CIK 0001776505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,418 F1 · shares: Grant of restricted stock awarded on September 30, 2021, as part of the Company's annual grant of equity awards to non-employee directors, pursuant to the 2013 Acacia Research Corporation Stock Incentive Plan. F1 · price: Grant of restricted stock awarded on September 30, 2021, as part of the Company's annual grant of equity awards to non-employee directors, pursuant to the 2013 Acacia Research Corporation Stock Incentive Plan. Read SEC document |
| June 18, 2019 Filed Jun 19, 2019 15:57 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | OtherACTG Common Stock | 6,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001776505-19-000006 · wf-form4_156095981768477.xml · nonDerivative · entry 1 Kohlberg Isaac T. · CIK 0001776505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On June 18, 2019, the Reporting Person returned his shares of common stock to the issuer for cancellation. Read SEC document |
| May 08, 2019 Filed May 13, 2019 21:33 UTC | ACACIA RESEARCH CORP ACTG · Entity 5559 | GrantACTG Common Stock | 6,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001776505-19-000004 · wf-form4_155778318724279.xml · nonDerivative · entry 1 Kohlberg Isaac T. · CIK 0001776505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,410 F1 · price: Grant of Restricted Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.